stockrow
Friday 6 November 2026
Export XGN’s income statement to Excel — free account
Exagen Inc.
XGN Healthcare Diagnostics & Research
Exagen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.6 million, up 19.7% from fiscal 2024.
- Revenue
- +15.9%
- EPS
- +38.1%
- Free cash flow
- +211.3%
- Total debt
- +6.44%
Quarter to June 2026, against a year earlier
5.80
1.80
−23.68%
Follow XGN
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 3 | 4 |
+8 more TTM periods Free account |
| (113.82%) | (193.58%) | (147.85%) | (122.81%) | ||
| (34.19%) | (43.72%) | (38.85%) | (35.78%) | ||
ROIC |
(68.33%) | (50.19%) | (87.10%) | (103.05%) | |
Return on Tangible Assets |
(52.62%) | (53.59%) | (47.88%) | (40.34%) | |
Average Days of Receivables |
63.67 | 84.19 | 59.51 | 63.66 | |
Free Cash Flow per Share |
(0.31) | (0.59) | (0.66) | (0.48) | |
Free Cash Flow |
(7.58) | (14.12) | (14.25) | (10.99) | |
Capital Expenditures |
(1.08) | (0.75) | (0.63) | (0.74) | |
| Other line items | |||||
Cash ROIC |
(12.37%) | (23.29%) | (19.12%) | (13.93%) | |
Accounts Receivable Turnover |
5.33 | 4.48 | 7.12 | 6.21 | |
Accounts Payable Turnover |
8.47 | 6.58 | 6.70 | 10.95 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
55.07 | 53.26 | 54.57 | 50.88 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8.71% | 8.85% | 0.00% | 9.67% | |
Selling, General and Administrative Expense of Revenue |
68.12% | 69.43% | 70.02% | 69.80% | |
Share Based Compensation of Revenue |
4.12% | 3.50% | 3.24% | 2.97% | |
Interest Coverage |
(2.58) | (2.80) | (3.26) | (3.51) | |
Operating CF/Net income |
0.34 | 0.66 | 0.68 | 0.54 | |
Depreciation/Fixed assets |
0.66 | 0.63 | 0.47 | 0.36 | |
Capex/Depreciation |
(0.25) | (0.18) | (0.19) | (0.27) | |
Revenue per Share |
2.94 | 2.87 | 3.09 | 2.77 | |
Operating CF per Share |
(0.27) | (0.56) | (0.63) | (0.45) | |
Capex per Share |
(0.04) | (0.03) | (0.03) | (0.03) | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 25 Oct 2026